OUR HISTORY AND DEVELOPMENT

On January 6, 2017, our Shareholders resolved to issue 34,750,000 Shares at an aggregate
consideration of RMB319,700,000 (being RMB9.2 per Share (representing a discount of
approximately 47.87% to our mid-point Offer Price of HK$19.88), which was determined after
arm’s length negotiation with reference to our industry, our core competitiveness and the
price-to-book ratio) to four investors, namely, Zhou Yuqing (周玉清), Shanghai Tanying,
Zhong Lu (鍾鷺) and Zhao Xigen (趙喜根), for purpose funding various stages of clinical
research on anti-PD-1 monoclonal antibody, anti-TNF-␣ monoclonal antibody, anti-BLyS
monoclonal antibody and anti-PCSK9 monoclonal antibody, the construction of the Lingang
Production Base and injecting capital
the
consideration had been settled in cash. Subsequently, our registered capital was increased from
RMB550,000,000 to RMB584,750,000, the registration of which with the Administration for
Industry and Commerce was completed on July 5, 2017.

into TopAlliance. As of February 24, 2017,

Set out below are the shareholding of the above investors as of the Latest Practicable Date

and immediately following the completion of the Global Offering:

Shareholding
immediately
following
completion of
the Global
Offering

Shareholding as
of the Latest
Practicable Date

(approximate)

(approximate)

5.11%
8.44%
0.41%
0.30%

4.04%
6.68%
0.33%
0.24%

Name

Zhou Yuqing (周玉清)
Shanghai Tanying
Zhong Lu (鍾鷺)
Zhao Xigen (趙喜根)

Note:

Assuming the Over-allotment Option is not exercised and without regard to the 2018 Convertible Bonds and
the Pre-IPO Options, and that they will not acquire or dispose of their Shares from the Latest Practicable Date
up to the completion of the Global Offering.

length negotiation with reference to our

On February 23, 2018, our Shareholders resolved to issue 16,650,000 Shares at an
aggregate consideration of RMB299,700,000 (being RMB18 per Share (representing a
premium of approximately 2.00% to our mid-point Offer Price of HK$19.88), which was
determined after arm’s
industry, our core
competitiveness and the price-to-book ratio) to three investors, namely, Xiamen Gaoxinhong
Equity Investment Co., Ltd.* (廈門市高鑫泓股權投資有限公司), Shanghai Tanying and Shen
Chun (沈淳), for the purposes of funding clinical research on JS001 and the construction of the
Lingang Production Base. As of March 7, 2018, the consideration had been settled in cash.
Subsequently,
to
Industry and
RMB601,400,000,
Commerce was completed on April 2, 2018.

the registration of which with the Administration for

from RMB584,750,000

our

registered

capital was

increased

– 167 –

